13/03/2018 18:00:00

Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing

SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it has completed a Series B financing which raised $63.5 million in new funds. The investment was led by Perceptive Advisors and includes new investors RA Capital and OrbiMed. Existing investors 5AM Ventures, Versant Ventures and Vivo Capital participated in the financing as well. Crinetics Pharmaceuticals plans to use the proceeds to fund the continuing development of CRN00808, an oral nonpeptide somatostatin agonist for the potential treatment of acromegaly, to develop additional new targeted therapeutics for endocrine disorders and endocrine related cancers, and for general corporate purposes.

“I am delighted to have some of the world’s most prominent healthcare investors join us for this important next phase of the company’s growth,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “This fundraising puts us on a strong financial footing that allows us to further the development of CRN00808 and advance our pipeline of additional internally-discovered drug programs. We believe Crinetics is poised to make a meaningful contribution to the treatment of rare endocrine disorders and today’s successful fundraising validates that promise and our strategy to date.” 

"Crinetics scientists are expanding the boundaries of our existing knowledge of GPCRs and how to target them with drugs," said Joseph Edelman, Founder and CEO of Perceptive Advisors. "Crinetics' current programs, all discovered in-house, have the potential to treat patients with conditions such as acromegaly, neuroendocrine tumors, hyperinsulinism and Cushing's disease. There is considerable unmet need in rare endocrine disorders, and we are excited to be a part of this effort to bring new options to patients and their physicians.”

In conjunction with this financing, the company also announced that, Weston Nichols, Ph.D., and Matthew K. Fust have joined Crinetics’ board of directors. Dr. Nichols is an analyst at Perceptive, while Mr. Fust has acted as Senior Advisor, Finance to the company since 2015. Additionally, Mahendra G. Shah, Ph.D., is stepping down from the board and will be replaced by Jack B. Nielsen. Mr. Nielsen is a Managing Director at Vivo Capital.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical-stage biotechnology company focusing on treatments for rare endocrine disorders and endocrine-related cancers. The company is currently conducting a Phase 1 trial with its oral nonpeptide somatostatin agonist, CRN00808, for the treatment of acromegaly, an orphan disease affecting more than 24,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for hyperinsulinism and neuroendocrine tumors, as well as an oral small molecule for Cushing's disease. Crinetics was founded by a team of scientists with a proven track record of endocrine drug discovery and development. The company is backed by top life sciences investors and is headquartered in San Diego. For additional information please visit www.crinetics.com

Contacts:

Marc Wilson

Chief Financial Officer

IR@crinetics.com

(858) 450-6464

Robert H. Uhl

Westwicke Partners

robert.uhl@westwicke.com

(858) 356-5932

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Jun
I:SP500
  Hejsa alle sammen   Konjunktur: Ifølge vedlagte teoretiske model omkring de ledende indikatorer be..
49
20 Jun
GEN
Et gammelt indlæg:   Hvis man kigger lidt tilbage i tiden og ser på de kvartalsvise resultater, så l..
36
24 Jun
VWS
Så vidt jeg kan se. har ingen andre i forumet kommenteret Makes ret opsigtsvækkende revurdering af u..
20
20 Jun
GEN
Hold da kæft, du er godt nok en sur (gammel ?) mand......
16
23 Jun
 
USA blev løftet ud af recession under Obama. Punktum. Økonomien kørte fint da Trump blev valgt og er..
14
19 Jun
VWS
https://www.vestas.com/en/media/company-news?n=1763161#!NewsView
12
19 Jun
I:SP500
Trump har bedt det amerikanske handelsministerie om en liste over kinesiske varer for 200 mia USD, s..
12
18 Jun
BAVA
Dvs de bør være der indenfor 9 børsdage... Hvis disse data gentager det som er kommet frem indtil nu..
12
24 Jun
ZEAL
Zealand Pharma har udsendt to meddelser om fremlæggelse af studier på American Diabetes Association ..
11
20 Jun
NOVO-B
Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenl..
11

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SHAREHOLDER ALERT: ALGT ESPR FLEX PPG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
2
Larson Electronics LLC Releases Explosion Proof Emergency LED Exit/KELUAR Sign
3
MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients
4
SeaBird Exploration Plc: SeaBird appoints new CEO
5
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 June 2018 09:05:53
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB2 - 2018-06-25 10:05:53 - 2018-06-25 09:05:53 - 1000 - Website: OKAY